Statistics from Altmetric.com
ABSTRACT FROM: Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015;76:e487–98.
What is already known on this topic?
Several strategies have been proposed for patients with treatment-resistant depression (TRD), including dose optimisation, switching to another therapeutic class or combination/augmentation regimens,1 however, it is still not known how the different strategies compare with each other. Zhou and colleagues specifically examined augmentation strategies for efficacy and acceptability in a network meta-analysis of randomised controlled trials (RCTs).
Methods of the study
PubMed, the Cochrane Library, clinical trial registries and drug company websites were searched for published/unpublished RCTs comparing augmentation strategies (or placebo) for the acute treatment of adults with TRD (defined as major depressive disorder with previous failure and current non-response to at least one oral, first-line, therapeutically dosed antidepressant drug). Original study authors and drug manufacturers were contacted. RCTs …
Competing interests CA receives support from Sun Pharmaceuticals (money paid to charities), receives authorship royalties from Zydus Neurosciences, as well as grants from the Indian Council for Medical Research, the Department of Biotechnology, and the Department of Science and Technology.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.